Get involved in the discussion! Click here to comment on this story
DuPont’s nutrition and bioscience business may be up for sale and Amsterdam’s Royal DSM may want to buy it, according to a report from Bloomberg.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The business could be valued at $25 billion, people who asked not to be identified told Bloomberg.
The specialty chemicals maker has been considering the sale or spinoff of its nutrition business, and has been in the process of selecting advisers to sort out offers for the division for some time, according to confidential sources.
In August, Bloomberg said that DuPont wanted to rid itself of the arm, and may be looking into a Reverse Morris Trust, a tax-free merger, as well.
Shares of DuPont fell 1.41% to $72.50 on Monday.
By Cherella Cox Owoyelu
Source: The Street
LinkedIn Twitter FacebookLonza Chief Executive Marc Funk is leaving the Swiss chemicals company after less a year in the job, it said on Tuesday, citing personal reasons. Funk, who has […]
LinkedIn Twitter FacebookSpain’s second general election this year has delivered another hung parliament which could make governability difficult. The chemical sector is hopeful, however, that a cabinet led by the […]
LinkedIn Twitter FacebookGerman chemicals group BASF has asked the two remaining private-equity suitors of its 3 billion euro ($3.3 billion) construction chemicals unit for final bids by Friday, three people […]
